CY-09 is primarily recognized for its role in inhibiting the NLRP3 inflammasome, a key component in the inflammatory response. This property makes it highly valuable in research focused on inflammatory diseases. It is used in studies to explore potential treatments for conditions like Alzheimer's disease, diabetes, and atherosclerosis, where NLRP3 activation plays a significant role. By targeting this pathway, CY-09 helps in understanding the mechanisms of inflammation and developing therapeutic strategies to mitigate chronic inflammatory disorders. Its application extends to preclinical models, where it aids in evaluating the efficacy of inflammasome inhibition in disease progression and symptom management.